298 related articles for article (PubMed ID: 15630049)
21. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
[TBL] [Abstract][Full Text] [Related]
22. Cyclo-oxygenase-2 inhibition increases blood pressure in rats.
Höcherl K; Endemann D; Kammerl MC; Grobecker HF; Kurtz A
Br J Pharmacol; 2002 Aug; 136(8):1117-26. PubMed ID: 12163344
[TBL] [Abstract][Full Text] [Related]
23. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
24. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
Kitahara M; Eitner F; Ostendorf T; Kunter U; Janssen U; Westenfeld R; Matsui K; Kerjaschki D; Floege J
J Am Soc Nephrol; 2002 May; 13(5):1261-1270. PubMed ID: 11961014
[TBL] [Abstract][Full Text] [Related]
25. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
Aw TJ; Liew D; Tofler GH; Schneider HG; Morel-Kopp MC; Billah B; Krum H
J Hypertens; 2006 Oct; 24(10):1979-84. PubMed ID: 16957557
[TBL] [Abstract][Full Text] [Related]
26. Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression.
Waldner C; Heise G; Meyer-Kirchrath J; Schrör K; Grabensee B; Heering P
Nephron Exp Nephrol; 2003; 93(2):e72. PubMed ID: 12629275
[TBL] [Abstract][Full Text] [Related]
27. Nitric oxide synthase activity and renal injury in genetic hypertension.
Hayakawa H; Raij L
Hypertension; 1998 Jan; 31(1 Pt 2):266-70. PubMed ID: 9453314
[TBL] [Abstract][Full Text] [Related]
28. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.
López-Parra M; Clària J; Planagumà A; Titos E; Masferrer JL; Woerner BM; Koki AT; Jiménez W; Altuna R; Arroyo V; Rivera F; Rodés J
Br J Pharmacol; 2002 Feb; 135(4):891-900. PubMed ID: 11861316
[TBL] [Abstract][Full Text] [Related]
30. Rofecoxib decreases renal injury in obese Zucker rats.
Dey A; Maric C; Kaesemeyer WH; Zaharis CZ; Stewart J; Pollock JS; Imig JD
Clin Sci (Lond); 2004 Dec; 107(6):561-70. PubMed ID: 15307815
[TBL] [Abstract][Full Text] [Related]
31. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
Izhar M; Alausa T; Folker A; Hung E; Bakris GL
Hypertension; 2004 Mar; 43(3):573-7. PubMed ID: 14744921
[TBL] [Abstract][Full Text] [Related]
32. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
33. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
[TBL] [Abstract][Full Text] [Related]
34. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
35. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Widlansky ME; Price DT; Gokce N; Eberhardt RT; Duffy SJ; Holbrook M; Maxwell C; Palmisano J; Keaney JF; Morrow JD; Vita JA
Hypertension; 2003 Sep; 42(3):310-5. PubMed ID: 12874094
[TBL] [Abstract][Full Text] [Related]
36. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy.
Hayakawa H; Coffee K; Raij L
Circulation; 1997 Oct; 96(7):2407-13. PubMed ID: 9337217
[TBL] [Abstract][Full Text] [Related]
37. Abnormal expression of ENaC and SGK1 mRNA induced by dietary sodium in Dahl salt-sensitively hypertensive rats.
Aoi W; Niisato N; Sawabe Y; Miyazaki H; Tokuda S; Nishio K; Yoshikawa T; Marunaka Y
Cell Biol Int; 2007 Oct; 31(10):1288-91. PubMed ID: 17485228
[TBL] [Abstract][Full Text] [Related]
38. Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension.
Tian N; Thrasher KD; Gundy PD; Hughson MD; Manning RD
Hypertension; 2005 May; 45(5):934-9. PubMed ID: 15837840
[TBL] [Abstract][Full Text] [Related]
39. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Warner TD; Vojnovic I; Bishop-Bailey D; Mitchell JA
FASEB J; 2006 Mar; 20(3):542-4. PubMed ID: 16403783
[TBL] [Abstract][Full Text] [Related]
40. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
